Postmenopausal breast cancer
Conditions
Interventions
Toremifene (120mg) is orally administered once a day everyday.
Sponsors
Saitama Breast Cancer Clinical Study Group (SBCCSG)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. A written consent is obtained 2. Patients diagnosed histologically as having had breast cancer at primary lesion 3. Patients relapsed during or after winthin one year completion of anastrozole treatment 4. PS(ECOG):0-2 5. Patients having measurable lesion or assessable bone lesion 6. 7. Patients with expected lifetime for more than 3 months 8. Patients with bone metastasis without radiotherapy
Exclusion criteria
Exclusion criteria: 1. Patients under anti-estrogen hormone therapy 2. Patients under hormone therapy except for anastrozole 3. Patients diagnosed as inflammatory breast cancer 4. Patients with a history of deep venous thrombosis 5. Patients with serious complications A. Patients with ischemic heart disease or cardiac arrhythmia that need treatment(left ventricular hypertrophy or mild left ventricular load induced by hypertension,or mild right bundle-branch block is eligible) B. Patients with a history of myocardial infarction within 6 months onset C. Patietns with uncontrollable diabetes 6. Patients with brain metastasis 7. Patients taking raloxifen (belonging to SERM) for treatment of osteoporosis 8. Doctor's decision for exclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical benefit | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. clinical responce rate 2. progression free survival(PFS) 3. time to progression(TTP) 4. adverse events | — |
Countries
Japan
Contacts
Public ContactToshihiro Kai
Shintoshin Ladies' Mammoclinic Saitama Breast Cancer Clinical Study Group Executive office
Outcome results
None listed